Skip to content
Master Your Financial Future — Master Your Money — Financial Insights Unveiled — Explore Local Housing Market

Swixx Biopharma’s €2B acquisition talks draw major industry players

A high-stakes race for a pharmaceutical giant unfolds. With €900 million in revenue and 44 markets, Swixx Biopharma’s future hangs on a blockbuster bid.

,   and  Administrator
1 min read
This image is clicked in a room, where it looks like Store. There are so many bottles in this image...
This image is clicked in a room, where it looks like Store. There are so many bottles in this image and cans. There is a Banner in the middle which is indicating Supra brand. Bottom right corner there is a logo LM.

Swixx Biopharma’s €2B acquisition talks draw major industry players

Swiss pharmaceutical distributor Swixx Biopharma is in talks for a potential acquisition, with estimates valuing the deal at up to €2 billion ($2.2 billion). The company, which specializes in navigating distribution in smaller and regulated markets, could fetch a significant sum.

Swixx Biopharma operates in 44 countries and generated €900 million in revenue last year. The company's expertise in medication distribution has drawn interest from several parties. Besides DKSH Holding, private-equity firms SK Capital Partners and Lone Star are also evaluating bids.

DKSH Holding, valued at around 3.5 billion Swiss francs, runs a similar distribution and marketing platform across various sectors. The company is exploring this acquisition to expand its presence in the pharmaceutical industry.

Swixx Biopharma's strategic role in pharmaceutical distribution has sparked interest from multiple parties. With DKSH Holding exploring a potential acquisition and private-equity firms evaluating bids, the future of the company is set to change significantly. The deal, if finalized, could be worth up to €2 billion.

Read also:

Related

Latest